AMAG Pharmaceuticals (NASDAQ:AMAG) saw a sharp drop in its debt in the past week following the release of its actual results in sales. Although the pharma company saw its sales rise to a new record in this past year, investors are concerned as its top-selling drug, Makena, is set to lose its patent exclusivity in 2018. The maternal drug aid currently makes up 70% of AMAG's sales and with no defense to differentiate it from generics, investors are uncertain of how the company will be able to cope.
.png)
